These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16302715)

  • 1. [GnRH antagonists and benign prostatic hyperplasia].
    Comaru-Schally dM
    Ann Urol (Paris); 2005 Oct; 39 Suppl 3():S73-7. PubMed ID: 16302715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
    Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
    Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in the control of testicular function.
    Swerdloff RS; Wang C; Bhasin S
    Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L
    Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist Cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-80.
    Drewa T; Chlosta P
    Eur Urol; 2009 Feb; 55(2):e36-7; author reply e38-9. PubMed ID: 18703271
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
    Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.
    Siejka A; Schally AV; Block NL; Barabutis N
    BJU Int; 2010 Nov; 106(9):1382-8. PubMed ID: 20151966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drug therapies for benign prostatic hyperplasia.
    Bullock TL; Andriole GL
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):111-23. PubMed ID: 16503830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LH-RH analogues: I. Their impact on reproductive medicine.
    Schally AV
    Gynecol Endocrinol; 1999 Dec; 13(6):401-9. PubMed ID: 10685334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of benign prostatic hypertrophy.
    Geller J
    Urology; 1989 Oct; 34(4 Suppl):57-63; discussion 87-96. PubMed ID: 2477935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Will GnRH antagonists improve prostate cancer treatment?
    Huhtaniemi I; White R; McArdle CA; Persson BE
    Trends Endocrinol Metab; 2009 Jan; 20(1):43-50. PubMed ID: 19008119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia.
    Kumar R; Malla P; Kumar M
    Expert Opin Drug Discov; 2013 Aug; 8(8):1013-27. PubMed ID: 23662859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Gres AA; Arustamov DL
    Eur Urol; 2008 Jul; 54(1):170-7. PubMed ID: 18417275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Ficarra V; Novara G
    Eur Urol; 2008 Jul; 54(1):178. PubMed ID: 18417274
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.